Kalijn F. Bol
Nijmegen, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.
Journal: Journal for immunotherapy of cancer
Published: February 09, 2026
Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy?
Journal: Journal for immunotherapy of cancer
Published: December 05, 2025
Reversal of rare paraneoplastic syndromes in melanoma: fever and cutaneous melanosis.
Journal: Melanoma research
Published: November 24, 2025
Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines.
Journal: Research square
Published: November 24, 2025
Dosing, duration, and timing controversies in determining immune checkpoint inhibitor dosing regimens.
Journal: NPJ precision oncology
Published: August 07, 2025
Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease.
Journal: Investigative ophthalmology & visual science
Published: February 07, 2025
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 28, 2025
Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma.
Journal: Clinical and experimental immunology
Published: June 25, 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: May 01, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses.
Journal: The Lancet. Oncology
Published: January 02, 2024
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Journal: Nature communications
Published: May 09, 2023
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.
Journal: Nature communications
Published: May 09, 2023
Last Updated: 09/26/2026